TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01173588

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: yogurt added with bifidobacteria and soluble fiber (YBF)
Description: Yogurt in YBF was added with 1.5 g inulin/100 g and ≥5 x 107 CFU of bifidobacterium/mL

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: yogurt added with bifidobacteria and soluble fiber (YBF)
Description: Yogurt in YBF was added with 1.5 g inulin/100 g and ≥5 x 107 CFU of bifidobacterium/mL
Study: NCT05504369

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic tape
Description: Tape with magnetic nanoparticles applied to the skin

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo tape
Description: Tape without nano particles applied to the skin
Study: NCT03039413

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo Cu-64-TP3805 Computed Tomography scan
Study: NCT02520934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miglustat
Description: combine miglustat and ERT to see if neurologic manifestations can be improved

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERT
Description: enzyme replacement therapy
Study: NCT02858076

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2-mg Intravitreous Aflibercept Injection
Description: Soluble decoy receptor fusion protein that has a high binding affinity to all isoforms of VEGF as well as to placental growth factor.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prompt Vitrectomy Plus Panretinal Photocoagulation
Description: Surgical removal of the vitreous gel and associated hemorrhage, concurrent delivery of panretinal endolaser
Study: NCT02460133

Intervention type: DRUG
Group type: OTHER
Intervention: Paritaprevir

Intervention type: DRUG
Group type: OTHER
Intervention: Ritonavir

Intervention type: DRUG
Group type: OTHER
Intervention: Dasabuvir

Intervention type: DRUG
Group type: OTHER
Intervention: Ombitasvir

Intervention type: DRUG
Group type: OTHER
Intervention: Ribavirin
Description: In genotype 1b individuals without cirrhosis, treatment will NOT include ribavirin.
Study: NCT00877214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Follicular Lymphomas: induction therapy with bendamustine + rituximab. If CR or PR: Maintenance therapy with rituximab every 2 months for 4 years Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab / observation
Description: Follicular Lymphomas:induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years (standard) Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: observation (standard)
Study: NCT00929864

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Syringes, Subcutaneous, 125 mg/syringe for Subcutaneous, Weekly Subcutaneous injections, 24 months (729 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Syringes, Subcutaneous, 40 mg, Biweekly Subcutaneous injections, 24 months (729 days)
Study: NCT02962869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987517
Description: 50 μl/ cm\*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. Twenty-four (24) hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm\*2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. Forty-eight (48) hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. (Formulation number: Z43-078)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Untreated skin
Description: One site is patched without treatment as control
Study: NCT03874533

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-adjustment tests
Description: For patients with an implant Cochlear™, we will be trained during workshop, to use a tablet how to do some tests ; They will do alone, by themselves the tests, just after the workshop and 8 to 30 days later.~Self audiometric test : digit triplet test, consonants discrimination test, Self-fitting of cochlear implant
Study: NCT03528967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg / 0.4 mL Prefilled Syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg Oral Tablet, Enteric Coated

Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin 100 mg Oral Tablet, Enteric Coated
Study: NCT00388115

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Standard of care lumpectomy or mastectomy following RFA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: Standard of care lumpectomy or mastectomy following RFA
Study: NCT02752620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Therapy
Study: NCT00388115

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Description: A small diameter needle is inserted through the skin and directly into the tumor for the purpose of supplying RF current. Initial power of the RF generator will start at 5-10 watts. The power will increase by 5-10 watts every minute until impedance of the system automatically stops the RF treatment.
Study: NCT02515461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low energy shockwave therapy
Description: Procedure: The patient lies on supine position during treatment. Kidney will be localised in line ultrasound. 3000 shockwaves at a frequency of 4 Hz are applied to each kidney per session. The kidney will be divided into three treatment areas including 1000 shockwaves applied to each treatment area.~Patients will receive 6 sessions over 3 weeks. Treatments are carried out on day 1, day 3, day 7, day 10, day 14, and day 17 after enrollment (average time points).~Treatment is performed using the MODULITH SLX-F2, manufactured by STORZ MEDICAL AG.
Study: NCT01305265

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cuff manometer
Description: endotracheal tube cuff will be inflated to 22-26 cm H20 using cuff manometer
Study: NCT02865642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serotonin Uptake Inhibitors

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02029313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast sodium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast sodium
Study: NCT00647426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib + Docetaxel/Carboplatin
Description: 400 mg po BID Sorafenib + 75 mg/m2 IV Docetaxel on day 1 plus AUC 6 on Carboplatin on day 1 of each 21 day cycle
Study: NCT01485588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hI-con1™ 60µl
Description: Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hI-con1™ 150µl
Description: Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hI-con1™ 300µl
Description: Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only
Study: NCT01909388

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI-TRUS fusion guided real time HDR
Study: NCT01350531

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills training
Description: This component includes skills most proximal to adhering to the eating and weight loss plan (e.g., calorie counting, making healthy food choices, measuring food portions, scheduling snacks and meals, meal planning, completing food logs daily, following an exercise plan).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Contingency management uses behavioral principles to counteract the reinforcing mechanisms of food and inactivity.
Study: NCT01908998

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sandal
Description: Subjectes will be scored on the Y-Balance Test wearing an Orthaheel Sandal
Study: NCT03220893

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital Tomosynthesis Mammography
Description: Undergo DBT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Scintimammography
Description: Undergo MBI
Study: NCT03216174

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NESS-EFTR
Description: NESS-EFTR includes steps of laparoscopic seromuscular suturing, EFTR of the inverted stomach wall, and endoscopic mucosal suturing with endoloops and clips.
Study: NCT01308580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (XRP6258)
Description: Pharmaceutical form: Concentrate and solvent for solution for infusion~Route of administration: Intravenous
Study: NCT02549274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-rehabilitation + physiotherapy
Description: 2 training sessions in self-rehabilitation at the hospital and then a self-rehabilitation / day session + 14 physiotherapy sessions (2 by week)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy
Description: 14 physiotherapy sessions (2 by week)
Study: NCT02885259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: human immunoglobulin and one vial of recombinant human hyaluronidase
Study: NCT01227954

Intervention type: RADIATION
Group type: OTHER
Intervention: intensity-modulated radiation therapy
Description: 30 Gy in 10 fractions to the whole brain using intensity-modulated radiation therapy excluding the hippocampal avoidance area. Bilateral hippocampal contours manually generated on the fused planning MRI CT image set by the treating physician according to protocol-specified contouring instructions. Hippocampal avoidance regions generated by three-dimensionally expanding the hippocampal contours by 5 mm.
Study: NCT01885507

Intervention type: OTHER
Intervention: Pass recommendations on ventilation factors and extubation
Description: * the use of tidal volume \< 7 ml/kg and of a positive expiratory pressure = 6 to 8 cmH20 (centimeter of water)~* extubation as soon as ventilatory weaning is associated with a glasgow coma scale equal or above 10 and cough
Study: NCT04189406

Intervention type: OTHER
Intervention: Venapunction
Description: A blood sample of 3.5 mL (0.2 mL serum for FSH and LH, 0.15 mL serum for E2, 0.15 mL serum for T, 0.15 mL serum for AMH and 0.25 mL serum for Inhibin B) will be collected of all girls with TS at 3 months and 9 months of age. For the girls with TS, this will be collected with an extra venapuncture during a regular outpatient visit within the usual care.
Study: NCT00563524

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ILV-094
Description: SC and IV administration on days 1, 14, 28, and 42
Study: NCT01728363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic
Description: Ticarcillin-clavulanate/Timentin is an antibiotic used to treat a wide variety of bacterial infections. Rifampin/Rifadin/Rimatane is an antibiotic and first line antituberculotic. Clindamycin/Cleocin is an antibiotic used to treat a wide variety of bacterial infections and serious bacterial infections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic
Description: Ticarcillin-clavulanate/Timentin is an antibiotic used to treat a wide variety of bacterial infections. Rifampin/Rifadin/Rimatane is an antibiotic and first line antituberculotic. Clindamycin/Cleocin is an antibiotic used to treat a wide variety of bacterial infections and serious bacterial infections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic
Description: Ticarcillin-clavulanate/Timentin is an antibiotic used to treat a wide variety of bacterial infections. Rifampin/Rifadin/Rimatane is an antibiotic and first line antituberculotic. Clindamycin/Cleocin is an antibiotic used to treat a wide variety of bacterial infections and serious bacterial infections.
Study: NCT04440007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abivertinib
Description: Abivertinib maleate is a third-generation EGFR tyrosine kinase inhibitor and BTK Inhibitor. The starting dose is 200 mg p.o. QD for up to 28 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care as determined by the Investigator

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care as determined by the Investigator
Study: NCT03672396

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based exercise
Description: The intervention consists of aerobic and strength training \~3 times per week for 12 weeks with each session lasting 1 hour. The progressive aerobic exercise will involve walking that varies from from 15 to 30 minutes done 2-4 times per week at an intensity from 40% to 65% of heart rate reserve. Therabands elastic bands will be used to perform 12 to 15 repetitions per exercise. Once a participant can comfortably complete 15 repetitions for all prescribed sets, they will increase resistance by moving up to the next band. The training volume increased from 1 set per exercise on week 1 to 3 sets by week 12.
Study: NCT04840628

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance of the respiratory system
Description: increase the resistance of the respiratory system of the chronic obstructive pulmonary disease patients
Study: NCT04033627

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In Vitro T cells depletion using CliniMCAS system
Description: Use the CliniMACS TCRα/β and CD45 Systems to deplete TCRα/β+ and CD45RA+ cells from the mobilized peripheral blood stem cells of a haploidentical donor in patients with leukemia.
Study: NCT02386722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartinhaler/POEMS with audio reminders and additional support calls
Description: Patients assigned to the intervention group will receive a Smartinhaler/POEMS, which will contain an audio reminder function. If the alarm function is on, a ring tone will be generated, after the time predesigned for inhalation. If the use of rescue medication doubles or if the inhaled medication is not inhaled as prescribed for more than two consecutive days, the investigator will call them to see if they need help and to find out the reason for non-adherence.
Study: NCT01208168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAB001
Description: nail lacquer, once daily, 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle alone
Description: nail lacquer, once daily, 52 weeks
Study: NCT02040207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM-101
Description: AM-101 gel for intratympanic injection
Study: NCT01424618

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide
Description: leuprolide 10 units daily, decreased to 5 units daily once suppression achieved for a total of approximately 4 weeks. Once suppression achieved, estradiol and progesterone administered to mature uterine lining.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix
Description: Ganirelix 250 mcg daily will be used to suppress pituitary-ovarian function and is administered concurrently with estradiol and progesterone for approximately two weeks.
Study: NCT03235973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine-Cladribine-Busulfan conditioning regimen
Description: Conditioning regimen will be performed from day -6 to day -2 and contains:~* Fludarabine 10 mg/m²/d during 5 days (day-6 to day-2).~* Cladribine during 5 days (day-6 to day-2) at one the following define dose level:~  * Dose 1: 10 mg/m²/d~ * Dose 2: 15 mg/m²/d~ * Dose 3: 20 mg/m²/d~ * Dose 4: 25 mg/m²/d~* IV busulfan will be given on day-6 using fixed dose as following:~  * If age ≤ 60 years: starting dose of 130 mg/m²~ * If age \> 60 years: starting dose of 100 mg/m² No busulfan will be administered at day-5, allowing the pharmacokinetic (PK) analyses . Subsequent infusion of IV busulfan will be performed from day-4 to day-2 at the dose recommended by PK analyses
Study: NCT03757741

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac imaging tests
Description: 2D transthoracic echocardiography; Late gadolinium-enhancement cardiac magnetic resonance with the evaluation of pulmonary veins anatomy, atrial fibrosis, atrial volumes and the amount of epicardial fat will

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac imaging tests
Description: 2D transthoracic echocardiography; Late gadolinium-enhancement cardiac magnetic resonance with the evaluation of pulmonary veins anatomy, atrial fibrosis, atrial volumes and the amount of epicardial fat will

Intervention type: DIAGNOSTIC_TEST
Intervention: Venous blood samle collection
Description: Venous blood sample collection 1 day prior to the ablation procedure: Serum levels of high sensitive C Reactive Protein, Matrix metalloproteases, Interleukin-6, and N-Terminal Pro-B-Type Natriuretic Peptide.

Intervention type: DIAGNOSTIC_TEST
Intervention: Venous blood samle collection
Description: Venous blood sample collection 1 day prior to the ablation procedure: Serum levels of high sensitive C Reactive Protein, Matrix metalloproteases, Interleukin-6, and N-Terminal Pro-B-Type Natriuretic Peptide.
Study: NCT02413879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CleanCision
Description: Wound protection during colorectal surgery.
Study: NCT01308580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (XRP6258)
Description: Pharmaceutical form: Concentrate and solvent for solution for infusion~Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone (or Prednisolone)
Description: Pharmaceutical form: Tablet~Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone (or Prednisolone)
Description: Pharmaceutical form: Tablet~Route of administration: Oral
Study: NCT00374842

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix™
Description: GlaxoSmithKline Biologicals' licensed influenza vaccine
Study: NCT02149537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyurea
Study: NCT04075045

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellth Smartphone App
Description: Patients will receive the app that provides reminders to adhere to their self-care regimen and ability to track their daily adherence via photos of the self-care related items (medications, blood pressure cuff, meals).
Study: NCT00374842

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK1247446A
Description: Low-dose GlaxoSmithKline Biologicals' GSK1247446A influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK1247446A
Description: Low-dose GlaxoSmithKline Biologicals' GSK1247446A influenza vaccine
Study: NCT01629329

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin, Acetaminophen, Caffeine pills
Description: One time dose of 2 pills each containing acetaminophen 250mg, aspirin 250mg and caffeine 65mg in each tablet. Simultaneous administration of placebo(5ml of saline administered IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prochlorperazine 10mg
Description: One time dose of Prochlorperazine 10mg/2ml given IV slow push. Simultaneous administration of 2 unmarked placebo pills.
Study: NCT03871647

Intervention type: DRUG
Intervention: Beta blocker
Description: perioperative beta blockers

Intervention type: DRUG
Intervention: Beta blocker
Description: perioperative beta blockers
Study: NCT01365000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR118 Formulation 1
Description: Oral dose, 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR118 Formulation 2
Description: Oral dose, 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR118 Formulation 3
Description: Oral dose, 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR118 Formulation 1a
Description: Oral dose, 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR118 Formulation 3a
Description: Oral dose, 25 mg
Study: NCT02983578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danvatirsen
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study: NCT02899728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study: NCT04674345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity (dose range, 200-800 mg daily).
Study: NCT04602624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-718
Description: SAGE-718 oral tablets.
Study: NCT02076464

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: StudentBodies - Eating Disorders
Description: The intervention is a structured, cognitive-behavioral guided self-help program, derived from manual-based cognitive-behavioral therapy. The intervention targets the core eating disorder pathology (e.g., extreme dietary restraint, overvaluation of shape and weight, binge eating, compensatory behaviors), focusing on helping users develop regular eating patterns, self-control strategies, problem-solving skills, and relapse prevention tools for maintenance of behavior change. The program includes daily symptom checklists, journal exercises and activities, and an asynchronous moderated online discussion group.